Post-operative Atrial Fibrillation Clinical Trial
Official title:
Preemptive Pharmacogenetic- Guided Metoprolol Management for Postoperative Atrial Fibrillation in Cardiac Surgery: The PREEMPTIVE- Pilot Trial
Metoprolol is frequently administered to cardiac surgery patients to reduce the incidence of postoperative atrial fibrillation (PoAF). Metoprolol is metabolized by the enzyme CYP2D6, which is known to have many mutations that could influence a patient's ability to metabolize the drug. In this prospective clinical trial, the investigators will determine the genotype of CYP2D6 for patients undergoing cardiac surgery, provide an altered dosing recommendation for metoprolol, then report the relative effectiveness in managing PoAF for each pharmacogenetic- guided dosing category. The investigators will also explore the effects of personalized metoprolol dosing recommendations on outcomes in hospital length of stay, cost, and provider participation.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05223725 -
Gene Therapy for Post-Operative Atrial Fibrillation
|
Phase 1 | |
Recruiting |
NCT06124937 -
Empagliflozin to Prevent Post-Operative Atrial Fibrillation
|
Phase 3 | |
Completed |
NCT03779841 -
Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)
|
Phase 2 | |
Recruiting |
NCT04993456 -
Calcitonin Level and New-onset of Post-Operative Atrial Fibrillation
|
||
Completed |
NCT03525860 -
Acupuncture Treatment for Patients Who Develop Arrhythmias in the Post-Operative Cardio-Thoracic Setting
|
N/A | |
Completed |
NCT02701062 -
AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)
|
Phase 4 | |
Recruiting |
NCT02029534 -
Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)
|
Phase 4 |